A British pharmaceutical company is expressing optimism about a new cancer treatment following encouraging preliminary trial results that demonstrated the drug’s ability to reduce tumors in patients battling difficult-to-treat cancers.
GSK’s experimental medication Mo-rez has emerged as a top priority for the company after initial data revealed its effectiveness against advanced forms of cancer, according to Hesham Abdullah, the firm’s head of oncology research.
“This is one of our priority assets at this stage,” Abdullah told reporters during a briefing about the preliminary findings, which are scheduled for presentation at a medical conference in Puerto Rico on Sunday.
When asked about the drug’s commercial prospects, Abdullah expressed confidence in its potential success. “Do we think it would be a blockbuster? Yes, absolutely,” he stated during the media call.
The early trial results focused on measuring how many patients experienced significant tumor reduction, specifically looking for at least 30% shrinkage. Among women with platinum-resistant ovarian cancer, 62% achieved this benchmark, while 67% of endometrial cancer patients reached the same milestone.
These positive outcomes are providing new energy to GSK’s rapidly expanding cancer treatment division. The company’s new CEO Luke Miels, who assumed leadership in January, has committed to accelerating the development of innovative medications. Abdullah noted this strategic shift is already influencing their research approach.
“I think it has been reflected in the type of pace that you are seeing and the type of conviction that we have in our programmes moving forward,” Abdullah explained.
Currently, GSK is conducting Mo-rez trials in two advanced-stage studies focusing on ovarian and endometrial cancers, with plans to launch three additional research studies in the coming months.
The experimental treatment is classified as an antibody-drug conjugate that specifically targets the B7H4 protein present on gynecological cancer cells while avoiding healthy tissue. Industry projections estimate the market for these types of treatments could reach $31 billion by 2030.
GSK obtained licensing rights for the drug from Chinese company Hansoh Pharma in 2023. Financial analysts have not yet released sales forecasts for Mo-rez given the early stage of trial data.
